ARTICLE | Clinical News

GVAX vaccine for prostate cancer: Final Phase II data

July 28, 2008 7:00 AM UTC

Cell Genesys published in Cancer previously reported final data from the open-label, U.S. Phase I/II trial in 80 patients showing that median survival time was 35 months in the high-dose GVAX group, 2...